Compare CVI & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVI | ARQT |
|---|---|---|
| Founded | 1906 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.3B |
| IPO Year | 2006 | 2020 |
| Metric | CVI | ARQT |
|---|---|---|
| Price | $33.04 | $23.22 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $28.75 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 960.4K | 909.3K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.34% | N/A |
| EPS Growth | ★ 350.00 | 88.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,162,000,000.00 | $376,072,000.00 |
| Revenue This Year | $2.71 | $34.85 |
| Revenue Next Year | N/A | $29.39 |
| P/E Ratio | $126.29 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $19.50 | $12.42 |
| 52 Week High | $41.67 | $31.77 |
| Indicator | CVI | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 47.76 |
| Support Level | $25.11 | $22.56 |
| Resistance Level | $35.59 | $23.46 |
| Average True Range (ATR) | 1.46 | 0.92 |
| MACD | 0.09 | -0.10 |
| Stochastic Oscillator | 71.94 | 35.33 |
CVR Energy Inc is a holding company that engages in petroleum refining and nitrogen fertilizer manufacturing through its subsidiaries. Subsidiaries include several complex, full-coking crude oil refineries, along with a crude oil gathering system, pipelines, storage tanks, and marketing and supply. The company's refineries can process blends of a variety of crude oil ranging from heavy sour to light sweet crude oil. Crude oil for CVR's refineries is supplied through its wholly-owned gathering system and pipeline. From its refineries, CVR supplies products through tanker trucks directly to customers located in close geographic proximity and customers at throughput terminals. The company's customers include retailers, railroads, and farm cooperatives.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.